NCT04229264 (AGRIPPA) is a Phase 3 clinical trial of Apixaban in Critical Limb Ischemia, sponsored by Science Valley Research Institute.

Who is sponsoring NCT04229264?

NCT04229264 is sponsored by Science Valley Research Institute.

What drugs are being tested in NCT04229264?

Interventions in NCT04229264: Apixaban, ASA, Clopidogrel 75mg.

What condition does NCT04229264 study?

NCT04229264 studies Critical Limb Ischemia.

Is NCT04229264 still recruiting?

NCT04229264 is currently status unknown. Last updated 20 April 2021.

Last reviewed 2021-04-20 · How we verify

NCT04229264: AGRIPPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

Status unknown Phase 3 Last updated 20 April 2021

What this trial tests

Phase 3 trial testing Apixaban in Critical Limb Ischemia in 200 participants. Status unknown.

Timeline

9 January 2020

Primary endpoint
2 February 2022

2 May 2022

Quick facts

Lead sponsor	Science Valley Research Institute
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	9 January 2020
Primary completion	2 February 2022
Estimated completion	2 May 2022
Sites	1 location across Brazil

Drugs / interventions tested

Apixaban (apixaban) — full drug profile →
ASA — full drug profile →
Clopidogrel 75mg — full drug profile →

Conditions studied

Critical Limb Ischemia — all drugs for Critical Limb Ischemia →

Sponsor

Science Valley Research Institute

Who can join

18 and older, any sex, with Critical Limb Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb ischemia undergoing infrapopliteal arterial endovascular intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
Biagioni RB, Lopes RD, Agati LB, Sacilotto R, et al · · 2020 · cited 13× · PMID 32730905 · DOI 10.1016/j.ahj.2020.06.010

Verify or expand the search:

Other trials of Apixaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07493304 — Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc · Phase 3 · not yet recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07404345 — Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dy · Phase 4 · not yet recruiting

Other recruiting trials for Critical Limb Ischemia

Currently open trials in the same condition.

NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT06434194 — Serrantor OCT Study · NA · recruiting
NCT06482892 — TP03HN106 in Patients With Critical Limb Ischemia · Phase 2 · recruiting
NCT06296576 — Acceleration Time Assessment for Prediction of Critical Limb Ischemia · recruiting
NCT06075940 — Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Diseas · NA · recruiting

Other Science Valley Research Institute trials

Trials by the same sponsor.

NCT06974526 — Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgica · Phase 2 · recruiting
NCT06958588 — Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis · Phase 4 · recruiting
NCT06980961 — Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis · NA · recruiting
NCT06873321 — VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization · Phase 4 · recruiting
NCT06136208 — Pharmacokinetic Aspects of 25-mg Estradiol Pellet in Climacteric Women · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04229264 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Science Valley Research Institute
Last refreshed: 20 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04229264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing